Subchronic <i>N</i>-acetylcysteine Treatment Decreases Brain Kynurenic Acid Levels and Improves Cognitive Performance in Mice

The tryptophan (Trp) metabolite kynurenic acid (KYNA) is an α7-nicotinic and <i>N</i>-methyl-<span style="font-variant: small-caps;">d</span>-aspartate receptor antagonist. Elevated brain KYNA levels are commonly seen in psychiatric disorders and neurodegenerative d...

Full description

Saved in:
Bibliographic Details
Main Authors: Tonali Blanco Ayala (Author), Daniela Ramírez Ortega (Author), Paulina Ovalle Rodríguez (Author), Benjamín Pineda (Author), Gonzalo Pérez de la Cruz (Author), Dinora González Esquivel (Author), Robert Schwarcz (Author), Korrapati V. Sathyasaikumar (Author), Anabel Jiménez Anguiano (Author), Verónica Pérez de la Cruz (Author)
Format: Book
Published: MDPI AG, 2021-01-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_6d1b4536c2694e4d955fd108de2f8072
042 |a dc 
100 1 0 |a Tonali Blanco Ayala  |e author 
700 1 0 |a Daniela Ramírez Ortega  |e author 
700 1 0 |a Paulina Ovalle Rodríguez  |e author 
700 1 0 |a Benjamín Pineda  |e author 
700 1 0 |a Gonzalo Pérez de la Cruz  |e author 
700 1 0 |a Dinora González Esquivel  |e author 
700 1 0 |a Robert Schwarcz  |e author 
700 1 0 |a Korrapati V. Sathyasaikumar  |e author 
700 1 0 |a Anabel Jiménez Anguiano  |e author 
700 1 0 |a Verónica Pérez de la Cruz  |e author 
245 0 0 |a Subchronic <i>N</i>-acetylcysteine Treatment Decreases Brain Kynurenic Acid Levels and Improves Cognitive Performance in Mice 
260 |b MDPI AG,   |c 2021-01-01T00:00:00Z. 
500 |a 10.3390/antiox10020147 
500 |a 2076-3921 
520 |a The tryptophan (Trp) metabolite kynurenic acid (KYNA) is an α7-nicotinic and <i>N</i>-methyl-<span style="font-variant: small-caps;">d</span>-aspartate receptor antagonist. Elevated brain KYNA levels are commonly seen in psychiatric disorders and neurodegenerative diseases and may be related to cognitive impairments. Recently, we showed that <i>N</i>-acetylcysteine (NAC) inhibits kynurenine aminotransferase II (KAT II), KYNA's key biosynthetic enzyme, and reduces KYNA neosynthesis in rats in vivo. In this study, we examined if repeated systemic administration of NAC influences brain KYNA and cognitive performance in mice. Animals received NAC (100 mg/kg, i.p.) daily for 7 days. Redox markers, KYNA levels, and KAT II activity were determined in the brain. We also assessed the effect of repeated NAC treatment on Trp catabolism using brain tissue slices ex vivo. Finally, learning and memory was evaluated with and without an acute challenge with KYNA's bioprecursor L-kynurenine (Kyn; 100 mg/kg). Subchronic NAC administration protected against an acute pro-oxidant challenge, decreased KYNA levels, and lowered KAT II activity and improved memory both under basal conditions and after acute Kyn treatment. In tissue slices from these mice, KYNA neosynthesis from Trp or Kyn was reduced. Together, our data indicate that prolonged treatment with NAC may enhance memory at least in part by reducing brain KYNA levels. 
546 |a EN 
690 |a <i>N</i>-acetylcysteine 
690 |a kynurenic acid 
690 |a kynurenine 
690 |a learning and memory 
690 |a Therapeutics. Pharmacology 
690 |a RM1-950 
655 7 |a article  |2 local 
786 0 |n Antioxidants, Vol 10, Iss 2, p 147 (2021) 
787 0 |n https://www.mdpi.com/2076-3921/10/2/147 
787 0 |n https://doaj.org/toc/2076-3921 
856 4 1 |u https://doaj.org/article/6d1b4536c2694e4d955fd108de2f8072  |z Connect to this object online.